Coronavirus Lounge

pubmed.ncbi.nlm.nih.gov

1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea - PubMed

The oncogenic potential of SARS-CoV-2 has been hypothetically proposed, but real-world data on COVID-19 infection and vaccination are insufficient. Therefore, this large-scale population-based retrospective study in Seoul, South Korea, aimed to estimate the cumulative incidences and subsequent...
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov

1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea​


The oncogenic potential of SARS-CoV-2 has been hypothetically proposed, but real-world data on COVID-19 infection and vaccination are insufficient. Therefore, this large-scale population-based retrospective study in Seoul, South Korea, aimed to estimate the cumulative incidences and subsequent risks of overall cancers 1 year after COVID-19 vaccination. Data from 8,407,849 individuals between 2021 and 2023 were obtained from the Korean National Health Insurance database. The participants were categorized into two groups based on their COVID-19 vaccination status. The risks for overall cancer were assessed using multivariable Cox proportional hazards models, and data were expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). The HRs of thyroid (HR, 1.351; 95% CI, 1.206-1.514), gastric (HR, 1.335; 95% CI, 1.130-1.576), colorectal (HR, 1.283; 95% CI, 1.122-1.468), lung (HR, 1.533; 95% CI, 1.254-1.874), breast (HR, 1.197; 95% CI, 1.069-1.340), and prostate (HR, 1.687; 95% CI, 1.348-2.111) cancers significantly increased at 1 year post-vaccination. In terms of vaccine type, cDNA vaccines were associated with the increased risks of thyroid, gastric, colorectal, lung, and prostate cancers; mRNA vaccines were linked to the increased risks of thyroid, colorectal, lung, and breast cancers; and heterologous vaccination was related to the increased risks of thyroid and breast cancers. Given the observed associations between COVID-19 vaccination and cancer incidence by age, sex, and vaccine type, further research is needed to determine whether specific vaccination strategies may be optimal for populations in need of COVID-19 vaccination.


Hyperinflamation also seems to be connected to covid injections:

Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review - PMC

The current SARS-CoV-2 pandemic diffused worldwide has encouraged the rapid development of vaccines to counter the spread of the virus. At present in Italy, 75.01% of the population completed the vaccination course (AIFA.gov.it) and very few adverse ...
pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov

They gave Anankira to some of them to cure from inflamation.

Inflamation is considered an hallmark of cancer:

www.cancer.gov

Treating Cancer by Reducing Tumor-Related Inflammation

Researchers are exploring whether people with cancer benefit from treatments that reduce inflammation around tumors. Some studies show promising results.
www.cancer.gov www.cancer.gov
 
magoo said:
pubmed.ncbi.nlm.nih.gov

1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea - PubMed

The oncogenic potential of SARS-CoV-2 has been hypothetically proposed, but real-world data on COVID-19 infection and vaccination are insufficient. Therefore, this large-scale population-based retrospective study in Seoul, South Korea, aimed to estimate the cumulative incidences and subsequent...
pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov

1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea​


The oncogenic potential of SARS-CoV-2 has been hypothetically proposed, but real-world data on COVID-19 infection and vaccination are insufficient. Therefore, this large-scale population-based retrospective study in Seoul, South Korea, aimed to estimate the cumulative incidences and subsequent risks of overall cancers 1 year after COVID-19 vaccination. Data from 8,407,849 individuals between 2021 and 2023 were obtained from the Korean National Health Insurance database. The participants were categorized into two groups based on their COVID-19 vaccination status. The risks for overall cancer were assessed using multivariable Cox proportional hazards models, and data were expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). The HRs of thyroid (HR, 1.351; 95% CI, 1.206-1.514), gastric (HR, 1.335; 95% CI, 1.130-1.576), colorectal (HR, 1.283; 95% CI, 1.122-1.468), lung (HR, 1.533; 95% CI, 1.254-1.874), breast (HR, 1.197; 95% CI, 1.069-1.340), and prostate (HR, 1.687; 95% CI, 1.348-2.111) cancers significantly increased at 1 year post-vaccination. In terms of vaccine type, cDNA vaccines were associated with the increased risks of thyroid, gastric, colorectal, lung, and prostate cancers; mRNA vaccines were linked to the increased risks of thyroid, colorectal, lung, and breast cancers; and heterologous vaccination was related to the increased risks of thyroid and breast cancers. Given the observed associations between COVID-19 vaccination and cancer incidence by age, sex, and vaccine type, further research is needed to determine whether specific vaccination strategies may be optimal for populations in need of COVID-19 vaccination.


Hyperinflamation also seems to be connected to covid injections:

Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review - PMC

The current SARS-CoV-2 pandemic diffused worldwide has encouraged the rapid development of vaccines to counter the spread of the virus. At present in Italy, 75.01% of the population completed the vaccination course (AIFA.gov.it) and very few adverse ...
pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov

They gave Anankira to some of them to cure from inflamation.

Inflamation is considered an hallmark of cancer:

www.cancer.gov

Treating Cancer by Reducing Tumor-Related Inflammation

Researchers are exploring whether people with cancer benefit from treatments that reduce inflammation around tumors. Some studies show promising results.
www.cancer.gov www.cancer.gov
Click to expand...
anakinra.jpgkinra1.jpg
 


"I know a sonographer who's been a sonographer for 40 years, and she reads ultrasounds. So she can read ultrasounds, and she can tell the mother, 'Oh, you got Pfizer, you got Moderna.' And if they're like, well, no, I didn't get the vaccine. Well, the placenta has these characteristics of this shot, and the dad is responsible for the, placenta health. And so the placenta will carry dad's DNA. So, if it's there, it's from dad. So even if the mother didn't receive the shot, but the dad did, it still will affect the baby... That mRNA Protein. It's in the sperm also...

"[And] the babies are still being born dead, and we're in 2025. And so mothers aren't necessarily receiving the COVID vaccines anymore. They are getting cov— They're getting vaccinated for TDAP, the flu. And then, like, RSV is a newer one. When they go to their doctor, they push all of these. So whether it's Covid or it's these new ones, I— I'm not sure. But the babies are still dying. And it's. Every time I go to work, there's a dead baby. And that, never should be normal.

"And I have asked many nurses— Are they okay with this? Yep. And they all say, I appreciate what you're doing. I believe you, but I can't lose my job."
 

Vaccine Stocks Drop After FDA Memo Links COVID Shots To Child Deaths​

Vaccine Stocks Drop After FDA Memo Links COVID Shots To Child Deaths | ZeroHedge

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
www.zerohedge.com www.zerohedge.com

Vaccine stocks slumped Monday after an explosive memo from FDA vaccine chief Vinay Prasad surfaced late Friday, signaling the agency is preparing to roll out tough restrictions on new vaccines for children. Prasad described a "profound revelation" linking Covid shots to at least ten deaths in children.

By late morning, Vaccine makers dropped on the memo: Moderna -6%, BioNTech -4.3%, Novavax -4%, Vaxcyte -6.6%.



"This is a profound revelation," Prasad wrote in the memo. "For the first time, the US FDA will acknowledge that COVID-19 vaccines have killed American children."



He added, "It is horrifying to consider that the US vaccine regulation, including our actions, may have harmed more children than we saved. This requires humility and introspection."



Wall Street analysts weighed in on the memo, and all agreed it introduces a new regulatory overhang for vaccine stocks.

Here's what the research desks told clients:

William Blair, Myles R. Minter (rates the MRNA market perform)

  • "Our interpretation of the memo is that CBER will focus its efforts on the younger 12- to 24-year-old male population for newly approved Covid-19 vaccines where the myocarditis risk is highest"
  • If new regulatory restrictions were to be implemented in the higher myocarditis risk population, analysts see further headwinds toward Moderna's declining Covid-19 franchise "alongside further negative sentiment that this memo and subsequent actions may generate"
  • Analyst says Pfizer, BioNTech, Novavax and Sanofi could also be impacted
  • "The memo also indicates several upcoming reforms to the CBER vaccine regulatory pathway, most notably the "demand" for pre- market randomized trials assessing clinical endpoints, not just immunogenicity, for most new vaccine products"
Mizuho, Salim Syed (rates PCVX outperform)

  • Says the memo notes "pneumonia vaccine makers will have to show their products reduce pneumonia (at least in the post- market setting), and not merely generate antibody titers"
  • However, "what investors are missing here is this is already in-line with the current standard" and poses no material change to Vaxcyte
Cantor, Carter Gould (rates PCVX overweight)

  • Says not surprised to see selloff in PCVX shares "on the back of the return of perceived regulatory risk after a period of relative calm, particularly with key data weighted to late 2026"
  • However, analyst says there wasn't much in the actual memo language on pneumococcal vaccines (PCVs) that's concerning
  • Reminds investors that "this all needs to continue to be viewed in the context of the likely timelines for VAX-31 adult and infants efforts against the backdrop of the time remaining in the current administration's term"
  • "We appreciate that there's plenty within the memo that's controversial or worrisome regarding Covid-19 vaccine policy, but the actual language on PCVs shows little evolution vs. prior guidance"
Leerink Partners, Mani Foroohar (rates MRNA underperform)

  • Says the memo's inflammatory tone highlights how agency policy/communications continue to contribute to vaccine skepticism and US vaccination rate decline
  • "We view this as a continued negative for mRNA vaccine manufacturers in our coverage– especially as it relates to Moderna's recently updated short-to-mid-term revenue guidance"
Click to expand...
The memo comes months after the Trump administration signaled it would link Covid shots to children's deaths. Remember, anyone who questioned the vaccines in the early days of the pandemic was demonized by Democrats and "trust the science" regime, which unleashed big-tech and state-sponsored censorship cartel against anyone asking questions.
 
You must log in or register to reply here.
Back
Top